Home › Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for...
 

Keywords :   


Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for...

2014-09-16 12:26:38| Chemicals - Topix.net

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer who have rising Prostate Specific Antigen levels and no detectable metastases.

Tags: iii begin trial phase

Category:Chemicals

Latest from this category

All news
27.11Jotun Discusses Shipping\'s Climate Role and Biodiversity at COP29
27.11 PPG Announces 50th Order for Electrostatic Marine Coating Application
26.11ROSS VersaMix Multi Shaft Mixers are for Complex Formulations
26.11PPG Completes Sale of Silicas Products Business to QEMETICA
26.11¦nie¿ka Among Leaders of Sustainable Development in Poland
26.11Solvay Unveils Climate and Water Projects in Brazil with HRH Princess Astrid of Belgium
25.11PPG Recognized in Newsweeks Americas Greenest Companies List
25.11Axalta Wins Another Distinguished R&D 100 Award for Innovation
Chemicals »
27.11Washington Corner | November 2024
27.11
27.11MTG 4
27.1119
27.11
27.11Y-3
27.11
27.1125th PSA10
More »